|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,653 GBX | +0.76% |
|
+3.38% | +13.98% |
| Apr. 25 | Sector Update: Health Care Stocks Drop in Afternoon Trading | MT |
| Apr. 25 | GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines | MT |
March 20 (Reuters) - British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United States, following similar moves by two of its rivals.
(Reporting by Leroy Leo in Bengaluru)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.98% | 84.13B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
GSK PLC 
